Ziprasidone Mesylate Injection, Powder, Lyophilized, For Solution
NDC Package 82449-004-01
Package Information
Ziprasidone Mesylate injection is ziprasidone injection is used to treat occurrences of severe agitation in patients with schizophrenia. This formulation utilizes a injection, powder, lyophilized, for solution delivery system. Marketed by Steriscience Specialties Private Limited, this product is identified by NDC 82449-004 and is authorized under FDA application ANDA217595.
Identification & Billing
- RxCUI: 351223 - ziprasidone 20 MG Injection
- RxCUI: 351223 - ziprasidone (as ziprasidone mesylate) 20 MG Injection
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 82449 - Steriscience Specialties Private Limited
- 82449-004 - Ziprasidone Mesylate
- 82449-004-01 - 1 VIAL, SINGLE-DOSE in 1 CARTON / 1 mL in 1 VIAL, SINGLE-DOSE
- 82449-004 - Ziprasidone Mesylate
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (82449-004). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 82449-004-01 identifies a specific commercial package of 1 vial, single-dose in 1 carton / 1 ml in 1 vial, single-dose of Ziprasidone Mesylate, a human prescription drug labeled by Steriscience Specialties Private Limited. This injection, powder, lyophilized, for solution is formulated for intramuscular use and contains ziprasidone mesylate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Steriscience Specialties Private Limited on December 19, 2025. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
Ziprasidone injection is used to treat occurrences of severe agitation in patients with schizophrenia. It works by helping to restore the balance of certain natural substances (neurotransmitters) in the brain. Ziprasidone injection is used when quick relief of your symptoms is required. It is not used together with the form of this medication that is taken by mouth. An injection of ziprasidone works quickly to reduce tension and anxiety which, if untreated, can result in dangerous behavior and interfere with your treatment and care.
How is this Steriscience Specialties Private Limited product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 82449000401. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.